Antipyrine as a model drug to study hepatic drug-metabolizing capacity

Journal of Hepatology

Volumn 6, Issue 3, 1988, Pages 374-382

  Poulsen, Henrik E ^a,b   Loft, Steffen ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PHENAZONE;

BIOTRANSFORMATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER FUNCTION TEST; PRIORITY JOURNAL; REVIEW;

ALGORITHMS; ANTIPYRINE; HUMAN; LIVER; LIVER FUNCTION TESTS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL;

EID: 0023892496     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(88)80057-6     Document Type: Review

References (62)

1. The fate of antipyrine in man
2. Two compartment analysis of plasma elimination of phenazone in normals and in patients with cirrhosis of the liver
3. Studies on the differential metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers
4. 14C in the pyrazolone ring or in the N-methyl group
5. Studies on the metabolic pathways of antipyrine in man: oral versus i.v. administration and the influence of urinary collection time
6. 3-Hydroxymethyl-antipyrine excretion in urine. A reconsideration of previously published data and synthesis of a pure reference substance
7. Comparison of plasma levels of antipyrine, tolbutamide and warfarin after oral and intravenous administration
8. Differential effects of enzyme induction on antipyrine metabolite formation
9. The absence of significant biliary excretion of antipyrine or its metabolites in human
10. Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man
11. Antipyrine metabolite formation and excretion in patients with chronic renal failure
12. Differential induction of antipyrine metabolism by rifampicin
13. Antipyrine metabolism during the menstrual cycle
14. Increased microsomal enzyme activity after surgery under halothane or spinal anesthesia
15. Influence of cimetidine on steady state concentration and metabolite formation from antipyrine infused with a rectal osmotic mini-pump
16. A simple method for determination of antipyrine clearance
17. Optimal sampling times for minimum variance of clearance determination.
18. A one-sample method for antipyrine clearance determinations in rats
19. Clearance of antipyrine-dependence of quantitative liver function
20. Cholic Acid Conjugation Test and Quantitative Liver Function in Acute Liver Failure
21. Antipyrine kinetics in liver disease and liver transplantation
22. Factors and conditions affecting antipyrine clearance and metabolite formation
23. Effect of rifampicin treatment on hepatic drug metabolism and serum-bile acids in patients with primary biliary cirrhosis
24. Antipyrine elimination in patients with obstructive jaundice: A prediction of outcome
25. Antipyrine clearance in patients with Gilbert's syndrome
26. Effect of surgery on liver function in patients with liver cancer
27. Monogenic control of variations in antipyrine metabolite formation
28. Genetic variations in rates of antipyrine metabolite formation: a study in uninduced twins
29. Family study of antipyrine clearance
30. Influence of sex and oral contraceptive steroids on antipyrine metabolite formation
31. Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man
32. Effects of parenteral nutritional regimens on oxidative drug metabolism
33. Effect of charcoal-broiled beef on antipyrine and theophylline metabolism.
34. Stimulatory effect of Brussel sprouts and cabbage on human drug metabolism
35. Antipyrine metabolism in man: influence of age, alcohol, caffeine and smoking
36. Ethanol and antipyrine clearance
37. Genetic and environmental factors affecting ethanol metabolism in man
38. Noninvasive assessment of microsomal enzyme activity in occupational medicine:
39. Hepatic drug metabolism and physical fitness
40. Influence of bed rest on the pharmacokinetics of phenazone
41. Hepatic microsomal enzyme activity with non-insulin-dependent diabetes (NIDD) and its clinical significance
42. Effects of grwoth hormone on antipyrine kinetics in children
43. Impaired lignocaine metabolism in patients with myocardial infarction and cardiac failure
44. Antipyrine clearance in pneumonia
45. The effect of fever on antipyrine metabolism in children
46. Hepatic antipyrine metabolism in malnourished patients: influence of the type of malnutrition and course after nutritional rehabilitation
47. Unaltered metabolism of antipyrine and tolbutamide in fasting man
48. Effect of surgery under general anaesthesia on antipyrine metabolism
49. Antipyrine metabolism in cancer patients
50. Variation of microsomal mixed function oxidase(s) and human lung cancer
51. Elimination of antipyrine and benzo[a]pyrene metabolism in cultured human lymphocytes
52. Interaction between metronidazole and drugs eliminated by oxidative metabolism
53. The effect of verapamil on antipyrine pharmacokinetics and metabolism in man
54. Diltiazem treatment impairs hepatic drug oxidation: studies of antipyrine
55. Influence of alaproclate on antipyrine metabolite formation in man
56. Effect of chloroquine and primaquine on antipyrine metabolism.
57. Effect of single and multiple doses of sulphinpyrazone on antipyrine metabolism and urinary excretion of 6-β-hydroxycortisol
58. Induction of mixed function oxidase activity by rifapentine (MDL 473), a long-acting rifamycin derivative
59. The effect of spironolactone on antipyrine metabolism in man
60. Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine.
61. Enzyme-inducing drug combinations and their effects on liver microsomal enzyme activity in man
62. Factors affecting the response to inhibition of drug metabolism by cimetidine-dose response and sensitivity of elderly and induced subjects